These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16388545)

  • 1. Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.
    James JS
    AIDS Treat News; 2005; (416):5-6. PubMed ID: 16388545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 3. Failure of combination abacavir + tenofovir + lamivudine (3TC).
    AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
    Khanlou H; Farthing C
    AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
    [No Abstract]   [Full Text] [Related]  

  • 5. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-HIV agents. Trying times for tenofovir and abacavir.
    TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
    TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
    [No Abstract]   [Full Text] [Related]  

  • 8. Investigating new antiretroviral combinations.
    Carr A
    J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
    [No Abstract]   [Full Text] [Related]  

  • 9. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
    [No Abstract]   [Full Text] [Related]  

  • 10. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
    Becker S; Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
    Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
    J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 16. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
    Berger DS
    Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 18. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.
    Gilliam BL; Sajadi MM; Amoroso A; Davis CE; Cleghorn FR; Redfield RR
    AIDS Patient Care STDS; 2007 Apr; 21(4):240-6. PubMed ID: 17461718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of gender and anchor drugs on TDF renal toxicity.
    Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.